Literature DB >> 10520043

Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0.

A Blann1, J Hewitt, F Siddiqui, D Bareford.   

Abstract

Warfarin is a commonly used prophylactic agent for the prevention of thromboembolic disease. We hypothesized that racial background influenced warfarin dosage, and tested this by recording the international normalized ratio (INR) in 867 patients aged 40-90 routinely passing through our Anticoagulation Service whose target INR was 2-3. Mean (95% confidence interval) dose was 4.1 (4.0-4.2) mg/d in 737 Caucasians, 5.5 (4.9-6.1) mg/d in 72 Asians, and 6.7 (5. 8-7.6) mg/d in 58 Afro-Caribbeans (P < 0.05) between each group). In a subgroup of 302 (41 Asians, 22 Afro-Caribbeans, 239 Caucasians), body mass index did not influence warfarin use. Despite small numbers, we conclude that racial background, but not body mass index, is a determinant of warfarin dosage. The reasons for this could be genetic, cultural (diet related), or both.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520043     DOI: 10.1046/j.1365-2141.1999.01672.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

Authors:  M A Perera; E Gamazon; L H Cavallari; S R Patel; S Poindexter; R A Kittles; D Nicolae; N J Cox
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation.

Authors:  D A Fitzmaurice; P Kesteven; K M Gee; E T Murray; R McManus
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

3.  Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance dose.

Authors:  Gin Gin Gan; Maude Elvira Phipps; Chee Seng Ku; Alan Teh; Vijaya Sangkar
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

4.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Authors:  Nihat Ozer; Nese Cam; Burak Tangurek; Songul Ozer; Huseyin Uyarel; Dilaver Oz; Mehmet Rasit Guney; Figen Ciloglu
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

5.  Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.

Authors:  N S Bazan; N A Sabry; A Rizk; S Mokhtar; O A Badary
Journal:  Ir J Med Sci       Date:  2013-06-27       Impact factor: 1.568

6.  Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients.

Authors:  Vivian W Y Lee; Joyce H S You; Kenneth K C Lee; T S Chau; Mary M Y Waye; Gregory Cheng
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

7.  Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

Authors:  Wenndy Hernandez; Keston Aquino-Michaels; Katarzyna Drozda; Shitalban Patel; Young Jeong; Harumi Takahashi; Larisa H Cavallari; Minoli A Perera
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

8.  Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Eunice Yuen; Ivelina Gueorguieva; Stephen Wise; Danny Soon; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-26       Impact factor: 2.745

9.  Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation.

Authors:  Albert Yuh-Jer Shen; Wansu Chen; Janis F Yao; Somjot S Brar; Xunzhang Wang; Alan S Go
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 10.  Polymorphism induced sensitivity to warfarin: a review of the literature.

Authors:  Michael P Palkimas; Hillary M Skinner; Pritesh J Gandhi; Alice J Gardner
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.